Addus HomeCare Corporation (ADUS) vs Clover Health Investments, Corp. (CLOV)

A side-by-side comparison of Addus HomeCare Corporation and Clover Health Investments, Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ADUS vs CLOV

growth of $100 · dividends reinvested · last 6y
ADUS +16.2% (+2.5%/yr)CLOV -53.6% (-12.0%/yr)ADUS compounded faster over this window
050100150200Start $100202120222023202420252026$116$46
ADUS CLOV

ADUS vs CLOV: by the numbers

  • •CLOV is the larger company ($2.43B vs $2.11B market cap).
  • •ADUS is profitable (7.13% net margin) while CLOV runs a net loss (-0.74%).
  • •CLOV grew revenue faster over the past five years (21.18% vs 12.67% CAGR).

Metrics side by side

Valuation

MetricADUSCLOV
P/E ratio19.82N/A
Forward P/E16.0383.51
PEG ratio0.98N/A
P/S ratio1.430.98
P/B ratio1.846.45
EV / EBITDA12.84N/A
FCF yield7.26%3.06%

Profitability

MetricADUSCLOV
Gross margin32.36%18.57%
Operating margin10.04%-0.74%
Net margin7.13%-0.74%
ROE9.17%-4.88%
ROIC8.61%-4.62%

Growth (annualized)

MetricADUSCLOV
Revenue CAGR (5Y)12.67%21.18%
EPS CAGR (5Y)19.61%N/A
FCF CAGR (5Y)24.41%N/A
Total return CAGR (5Y)8.33%-8.36%

Frequently asked

Which has grown faster, ADUS or CLOV?
Over the past five years, CLOV grew revenue faster — ADUS at a 12.67% CAGR versus CLOV at 21.18%.
Is ADUS or CLOV more profitable?
ADUS runs the higher net margin — ADUS at 7.13% versus CLOV at -0.74%.
How have ADUS and CLOV total returns compared?
Over the past 5 years, ADUS delivered 8.33% and CLOV delivered -8.36% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.